Listed

C4 Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2021

Filed with the SEC on May 13, 2021 and accepted by EDGAR at May 13, 2021, 16:38 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2021-01-01 to 2021-03-31$20.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-01-01 to 2021-03-31−$20.5mus-gaap:OperatingIncomeLoss
Net income3 months2021-01-01 to 2021-03-31−$21.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-01-01 to 2021-03-31−$0.49us-gaap:EarningsPerShareBasicAndDiluted
Basic EPS3 months2021-01-01 to 2021-03-31−$0.49us-gaap:EarningsPerShareBasic
Operating cash flow3 months2021-01-01 to 2021-03-31−$24.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2021-01-01 to 2021-03-31$421.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-03-31$94.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-03-31$322.0mus-gaap:AssetsCurrent
Total assetsAt period end2021-03-31$374.0mus-gaap:Assets
Current liabilitiesAt period end2021-03-31$37.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-03-31$110.3mus-gaap:Liabilities
Long-term debtAt period end2021-03-31$10.2mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2021-03-31$263.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-21-027606. Last ingested by Listed: Nov 14, 2026, 19:39 ET. Listed shows no prices and gives no investment advice.